Drug Trial Radar · NCT05991388
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
May 2, 2024
Primary completion
May 1, 2031
Study completion May 1, 2033
Sponsor
- Lead sponsor
- University of BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK; Fight Kids Cancer; Regeneron Pharmaceuticals; ADC Therapeutics S.A.
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL). B-NHL is a type of cancer that develops inside or outside of lymph nodes (glands) and organs such as the liver or spleen. Examples of B-NHL are Burkitt Lymphoma and Diffuse Large B Cell Lymphoma, which may be other names used to describe this type of cancer. It is very difficult to cure relapsed or refractory B-NHL. The medicines used now are very powerful with many side effects and only cure around 30 in every 100 children treated. It is very important that investigators quickly find better medicines for these children and young people. The Glo-BNHL trial will include three groups of children and young people, each given a new medicine (either alone or with chemotherapy). The investigators are looking to make sure the new medicines are safe and that they work to treat the cancer. If the medicine in one group does not work for a child in the trial, then they may be able to join a different group to have another new medicine. Experts from around the world will carefully pick the medicines most likely to be helpful to be part of the trial. If one of the new medicines seems not to be working as well as hoped then the investigators will take it out of the trial as soon as possible. This will let other new medicines be added to the trial and tested. If a medicine does seem to be working well, then it will continue in the trial to make sure it really is the most useful medicine available. Children from around the world will be invited to take part in the trial. The investigators will then check on them for at least two years after they finish the trial treatment to look for possible side effects of the new medicine.
Conditions
- B-cell Non Hodgkin Lymphoma
Interventions
OdronextamabDrug
CD20xCD3 bispecific antibody
Loncastuximab tesirineDrug
CD-19-directed antibody-drug conjugate
RituximabDrug
Modified R-ICE chemotherapy
IfosfamideDrug
Modified R-ICE chemotherapy
CarboplatinDrug
Modified R-ICE chemotherapy
EtoposideDrug
Modified R-ICE chemotherapy
Etoposide PhosphateDrug
Modified R-ICE (Treatment Arm II)
DexamethasoneDrug
Modified R-ICE chemotherapy
CAR T-cells (TBC)Biological
Modified R-ICE chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Arm I: BsAb: Occurrence of an objective response (OR)Time frame: At the end of week 12 of treatment
- Treatment Arm II: ADC with standard chemotherapy: Occurrence of CRTime frame: At the end of Cycle 2 and Cycle 3 of treatment (each cycle is 28 days)
Locations
11 sites in 7 countries. Site status is shown where the registry gives one.
The Children's Hospital at Westmead
Sydney, New South Wales, Australia · Not yet recruiting
Queensland Children's Hospital
Brisbane, Queensland, Australia · Not yet recruiting
Perth Children's Hospital
Perth, Washington, Australia · Recruiting
St. Anna Children's Hospital
Vienna, Austria · Recruiting
UZ Leuven
Leuven, Belgium · Not yet recruiting
Princess Máxima Centre for Pediatric Oncology
Utrecht, Netherlands · Recruiting
Starship Children's Hospital
Auckland, New Zealand · Not yet recruiting
Sahlgrenska University Hospital
Gothenburg, Sweden · Not yet recruiting
Birmingham Children's Hospital
Birmingham, United Kingdom · Recruiting
Bristol Royal Hospital for Children
Bristol, United Kingdom · Recruiting
Royal Manchester Children's Hospital
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.